Biogen discusses Alzheimer's research advancements at conference

Biogen Inc. participated in the Stifel 2025 Virtual CNS Forum Conference on March 18, 2025. Priya Singhal, the Head of Development, spoke at the event and shared updates about the company’s progress. During her remarks, Singhal emphasized the company’s commitment to improving their development pipeline. Over the past two years, Biogen has focused on reducing risks and targeting areas with potential for growth. They have made significant strides, especially in their Alzheimer's research. Singhal highlighted a key program, BIIB080, which is part of a Phase II study called CELIA. They have made changes to this study to speed up the process and expect to have results by 2026. Overall, Biogen is optimistic about its future and is prioritizing developments that could lead to successful treatments.